RNA Innovation Foundry Opens New Pathways for Researchers
3 December 2025 NCRIS-Enabled RNA Innovation Foundry at The University of Western Australia Opens New Pathways for Researchers Therapeutic Innovation Australia (TIA) welcomes the launch of the new RNA Innovation Foundry at The University of Western Australia in Perth, a national capability supported through the Australian Government’s National Collaborative Research Infrastructure Strategy (NCRIS). As a funding partner, […]
mRNA Innovation – Going Beyond Human Therapeutics
11 August 2025 NSW Develops World-First Foot and Mouth Disease Vaccine, with Support from TIA’s RNA Products capability Australia is now among a handful of countries with the capability to produce a vaccine to protect livestock against foot and mouth disease (FMD), following the announcement of a world-first mRNA vaccine developed through a $20 million […]
TIA joins ACRI to support the research infrastructure workforce
29 July 2025 Therapeutic Innovation Australia is proud to have joined the Academy for Collaborative Research Infrastructure (ACRI) as an institutional member. ACRI is a newly established, independent not-for-profit organisation with a mission to support the research infrastructure workforce in Australia. It aims to provide professional development tailored to the needs of facility staff, advocate […]
Pipeline Accelerator 2024-25 Round 2 Outcomes
24 June 2025 Therapeutic Innovation Australia (TIA), in partnership with Phenomics Australia, Bioplatforms Australia and ANSTO’s National Deuteration Facility, is thrilled to announce the successful recipients of the Pipeline Accelerator 2024-25 (Round 2). Enabled by the National Collaborative Research Infrastructure Strategy (NCRIS), all four NCRIS providers mentioned above are working together to help address the medical products challenge […]
200+ Reasons to Celebrate: TIA Launches Pipeline Accelerator Casebook
TIA is proud to announce the publication of our Pipeline Accelerator Casebook, a celebration of seven years of supporting therapeutic development across Australia through the Pipeline Accelerator scheme, a competitive funding initiative that helps academic researchers and SMEs access the facilities and expertise they need to progress promising health and medical innovations. The casebook brings together more than just individual stories […]
NCRIS Turbo-Charges New mRNA Drugs
Therapeutics that use mRNA are a growing area of development and work by introducing the ‘’message” to make a therapeutic protein into the patient’s body, instead of the protein itself. This approach can revolutionise combatting many kinds of cancers, and for treating genetic and infectious diseases. Conventional strategies deliver mRNA drugs to tissues inside lipid […]
BASE Facility Shares Open Protocol to Democratise mRNA Therapeutics
BASE Facility, supported by Therapeutic Innovation Australia (TIA) through the National Collaborative Research Infrastructure Strategy (NCRIS), has published a new open-access protocol that simplifies and streamlines the production of high-quality mRNA for research and preclinical applications. Published in Nature Protocols, this end-to-end guide walks researchers through the complete mRNA production workflow—from sequence design and DNA template […]
Building Australia’s RNA Biomanufacturing Workforce
Building Australia’s RNA Biomanufacturing Workforce: TIA Facilities Deliver Hands-On Training Several of Therapeutic Innovation Australia’s facilities are making major strides in workforce development through hands-on training programs that foster the next generation of RNA biomanufacturing experts. Recently, the UNSW RNA Institute launched its inaugural training program, offering four courses in RNA therapeutics manufacturing and quality […]
Major Investment for Psychiatric Drug Development
Co-founders Dr Greg Stewart, Associate Professor Jess Nithianantharajah and Professor Chris Langmead TIA’s Pipeline Accelerator Helps Phrenix Therapeutics Secure Major Investment for Psychiatric Drug Development Phrenix Therapeutics, a biotech company developing next-generation medicines for psychiatric and neurological disorders, has secured seed investment from Curie.Bio (US) and Brandon Capital (Australia). Therapeutic Innovation Australia (TIA) is proud to […]
Pipeline Accelerator Voucher Recipients Announced
Therapeutic Innovation Australia (TIA), in partnership with Phenomics Australia and the National Deuteration Facility (NDF), is thrilled to announce the successful recipients of the Pipeline Accelerator 2024-25 (Round 1). Supported through the National Collaborative Research Infrastructure Strategy (NCRIS), this initiative helps address the medical products challenge outlined in the 2021 National Research Infrastructure (NRI) Roadmap. […]
BioCurate and QEDDI Join Forces to Pioneer Safer Alternatives to Opioid Pain Relief
BioCurate and QEDDI (Queensland Emory Drug Discovery Initiative), a business unit of Uniquest, have announced a significant partnership aimed at developing an innovative treatment for neuropathic pain—a chronic condition affecting approximately 5% of the global population. This collaboration, supported by Therapeutic Innovation Australia (TIA) through the National Collaborative Research Infrastructure Strategy (NCRIS), seeks to provide […]
Advancing Groundbreaking Therapies for Spinal Cord Injury
A spinal cord injury treatment project has reached an exciting milestone, securing over $6.8 million in funding from the Medical Research Future Fund (MRFF) 2023 Stem Cell Therapies Grant. This funding will support a Phase I clinical trial testing an innovative therapy for spinal cord injury. The clinical trial will be a critical step in […]
Paving the Way for a Novel PAH Treatment: A Collaborative Effort
Pulmonary arterial hypertension (PAH) is a life-threatening disease that predominantly affects women, progressively causing damage to the pulmonary vessels, leading to heart failure. Current treatments are limited, offering only symptomatic relief without addressing the underlying disease. However, a breakthrough is on the horizon, thanks to a multidisciplinary team from Monash University, including the Australian Translational […]
QDDA Officially Launched: A New Era of Collaboration in Drug Discovery
The Queensland Drug Discovery Alliance (QDDA) is now officially launched following a successful event at the Translational Research Institute (TRI) in Brisbane on 14th October. The event brought together a diverse group of experts from across the sector to celebrate this pivotal moment in advancing drug discovery. The launch was opened by Stuart Newman, CEO of Therapeutic Innovation Australia (TIA), […]
Inaugural MedChem Australia Projects Announced
TIA congratulates the six recipients of the first round of the MedChem Australia application. Established in 2023, MedChem Australia is committed to helping translate innovative biomedical research into new medicines and commercial opportunities by connecting outstanding Australian science with medicinal chemistry and drug metabolism and pharmacokinetics (DMPK) expertise. Headquartered at the Monash Institute of Pharmaceutical Sciences in […]
Supercharging Queensland’s drug discovery pipeline
A $2 million grant awarded to establish the Queensland Drug Discovery Alliance (QDDA) will align and grow Queensland’s small molecule therapeutic discovery capability under the leadership of Therapeutic Innovation Australia (TIA). The funding from the Queensland Government’s Department of Environment, Science and Innovation (DESI) will unite and strengthen three flagship Queensland facilities: Compounds Australia (Institute […]
NSW Showcase: TIA and MTPConnect | Recent Visits to Leading Australian Research Facilities
On May 30th, the NSW Showcase event was hosted by TIA and MTPConnect. This event was dedicated to showcase Australia’s national research infrastructure for advancing therapeutic product developments. This showcase also provided detailed insights into available funding to support NCRIS access. Special guest Terry O’Riordan from AusIndustry gave an update on opportunities for matched grant […]